These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 28764705)
1. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. Wilke T; Mueller S; Lee SC; Majer I; Heisen M BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705 [TBL] [Abstract][Full Text] [Related]
2. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. Meissner B; Trivedi D; You M; Rosenblatt L J Med Econ; 2014 Apr; 17(4):259-65. PubMed ID: 24575891 [TBL] [Abstract][Full Text] [Related]
3. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553 [TBL] [Abstract][Full Text] [Related]
5. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W; Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837 [TBL] [Abstract][Full Text] [Related]
6. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry. Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971 [TBL] [Abstract][Full Text] [Related]
7. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL. Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD. Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512 [TBL] [Abstract][Full Text] [Related]
11. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810 [TBL] [Abstract][Full Text] [Related]
12. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt. Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276 [TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933 [TBL] [Abstract][Full Text] [Related]
14. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis. Baser O; Ganguli A; Roy S; Xie L; Cifaldi M Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184 [TBL] [Abstract][Full Text] [Related]
15. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971 [TBL] [Abstract][Full Text] [Related]
16. Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea. Park JA; Lee MY; Nam JH; Shin JY; Wood R; Holbrook T; Kwon SH Curr Med Res Opin; 2020 Feb; 36(2):343-351. PubMed ID: 31670976 [No Abstract] [Full Text] [Related]
17. Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Martins A; Pimenta S; Oliveira D; Nicolau R; Bernardo A; Martins Rocha T; Costa L; Bernardes M Reumatol Clin (Engl Ed); 2024; 20(7):380-385. PubMed ID: 39160010 [TBL] [Abstract][Full Text] [Related]
18. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil. Acurcio FA; Machado MA; Moura CS; Ferre F; Guerra AA; Andrade EI; Cherchiglia ML; Rahme E Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1489-96. PubMed ID: 26814681 [TBL] [Abstract][Full Text] [Related]
19. Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology. Carrara G; Argnani L; Zanetti A; Zabotti A; Silvagni E; Sebastiani GD; Sebastiani M; Scirè CA Scand J Rheumatol; 2022 Sep; 51(5):363-367. PubMed ID: 35023421 [TBL] [Abstract][Full Text] [Related]
20. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]